Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
There is a lack of data on how to treat hypertensive patients with diabetes when treatment with medium doses of calcium channel blocker and angiotensin II type 1 receptor blocker (ARB) is insufficient to achieve the target blood pressure (BP). A total of 121 participants with type 2 diabetes and uncontrolled essential hypertension, who were receiving medium doses of amlodipine (5 mg/day) and ARB, were enrolled. Participants were randomized to receive either a high dose of amlodipine (10 mg/day) plus a medium dose of ARB (high-AML) or a medium dose of amlodipine (5 mg/day) plus a high dose of ARB (high-ARB). The depressor effects of these two regimens were monitored using a telemonitoring home BP-measuring system. Fifty-four patients were excluded after an observation period, and the remaining 67 eligible participants were randomized into the two groups; 42 which had a record of their home BP for analysis. The change in morning home systolic and diastolic BP was greater in the high-AML than in the high-ARB (systolic BP; - 7.9 mmHg vs. + 2.7 mmHg; p = 0.0002, diastolic BP; - 3.9 mmHg vs. + 0.6 mmHg; p = 0.0007). In addition, the home systolic and diastolic BP before going to bed and office systolic BP were significantly reduced from week 0 only in the high-AML. An increased dose of amlodipine, but not ARB, reduced home morning BP in hypertensive patients with type 2 diabetes who were already receiving combination therapy with medium doses of amlodipine and ARB.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There appears to be inertia to treat residual hypertension in persons with T2D, and pharmacotherapy should be intensified when needed to achieve BP goals.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [248]
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,558
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
The Hawthorne Effect: a randomised, controlled trial
McCarney, R., Warner, J., Iliffe, S., van Haselen, R., Griffin, M., & Fisher, P. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-30 · Cited by 1,715
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792
Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001293 · Cited by 777
Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2014) · Blood Pressure · doi:10.3109/08037051.2014.868629 · Cited by 739
Renin-angiotensin system and cardiovascular risk
Schmieder, R. E., Hilgers, K. F., Schlaich, M. P., & Schmidt, B. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60242-6 · Cited by 663
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force* (2015) · Annals of Internal Medicine · doi:10.7326/m15-2223 · Cited by 491
Management of hypertension: summary of NICE guidance
Krause, T., Lovibond, K., Caulfield, M., McCormack, T., Williams, B., & on behalf of the Guideline Development Group (2011) · BMJ · doi:10.1136/bmj.d4891 · Cited by 477
Furuhashi, M., Ura, N., Higashiura, K., Murakami, H., Tanaka, M., Moniwa, N., Yoshida, D., & Shimamoto, K. (2003) · Hypertension · doi:10.1161/01.hyp.0000078490.59735.6e · Cited by 461
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395
Niiranen, T. J., Hänninen, M.-R., Johansson, J., Reunanen, A., & Jula, A. M. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.149336 · Cited by 390
Cardiovascular Outcomes in Framingham Participants With Diabetes: The Importance of Blood Pressure
Chen, G., McAlister, F. A., Walker, R. L., Hemmelgarn, B. R., & Campbell, N. R. C. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.162446 · Cited by 286
Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V
Tarnow, L., Rossing, P., Gall, M.-A., Nielsen, F. S., & Parving, H.-H. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1247 · Cited by 184
The epidemiology of impaired glucose tolerance and hypertension
Kannel, W. B., Wilson, P. W. F., & Zhang, T.-J. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90432-h · Cited by 178
Andraws, R., & Brown, D. L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.068 · Cited by 158
Current Status of Antihypertensive Prescription and Associated Blood Pressure Control in Japan
MORI, H., UKAI, H., YAMAMOTO, H., SAITOU, S., HIRAO, K., YAMAUCHI, M., & UMEMURA, S. (2006) · Hypertension Research · doi:10.1291/hypres.29.143 · Cited by 134
The role of adipokines in skeletal muscle inflammation and insulin sensitivity
Nicholson, T., Church, C., Baker, D. J., & Jones, S. W. (2018) · Journal of Inflammation · doi:10.1186/s12950-018-0185-8 · Cited by 126
Östergren, J., Poulter, N. R., Sever, P. S., Dahlöf, B., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328310e0d9 · Cited by 116
Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M., Fukuhara, S., & Iwasaka, T. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2005.04.008 · Cited by 88
Lender, D. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00259-3 · Cited by 79
Clinical estimation of fetal weight and the Hawthorne effect
Fox, N. S., Brennan, J. S., & Chasen, S. T. (2008) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2008.07.023 · Cited by 71
Xu, R., Sun, S., Huo, Y., Yun, L., Huang, S., Li, G., & Yan, S. (2015) · Medicine · doi:10.1097/md.0000000000001560 · Cited by 58
Sugihara, M., Miura, S., Takamiya, Y., Kiya, Y., Arimura, T., Iwata, A., Kawamura, A., Nishikawa, H., Uehara, Y., & Saku, K. (2009) · Hypertension Research · doi:10.1038/hr.2009.66 · Cited by 26
Self-citationPark, S., Park, J. B., Choi, D., Youn, H., Park, C. G., Ahn, Y. K., Shin, J., Kim, D. W., Rim, S., Bae, J. H., et al. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0492 · Cited by 18
Miyauchi, K., Yamazaki, T., Watada, H., Tanaka, Y., Kawamori, R., Imai, Y., Ikeda, S., Kitagawa, A., Ono, Y., Murayama, F., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1406 · Cited by 12
Treating hypertension in type 2 diabetes
Grossman, Y., Shlomai, G., & Grossman, E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.947267 · Cited by 11
Antihypertensive treatment, adiponectin and cardiovascular risk
Karthikeyan, V., & Lip, G. Y. H. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002113 · Cited by 8
Morii, J., Miura, S.-I., Ike, A., Shiga, Y., Sugihara, M., Iwata, A., Kawamura, A., Nishikawa, H., & Saku, K. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.9261 · Cited by 5
Self-citationAn Additional LDL-Lowering Effect of Amlodipine; Not Only an Antihypertensive?
Arslan, Z., Ay, S. A., Karaman, M., Çakar, M., Celık, T., Balta, Ş., Akhan, M., Şarlak, H., Arslan, E., Demirbaş, Ş., et al. (2012) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2012.746355 · Cited by 3
Research works printed but not linked: 1
- Okada T, Tanaka H, Kaisei E, Inoue T, Miyoshi H, Ono H, Kuwahara M, Miyake R (2013) Amlodipine10mg/ARB heiyouryouhou to, amlodipine5mg/ARB heiyouryouhou no kouatsukouka no hikakukentou. J Blood Press 20(11):1131–1137 (in Japanese)
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Morishima, M., & Ono, K. (2021) · Heart and Vessels · doi:10.1007/s00380-021-01853-8 · Cited by 4
Disruption of asparagine-linked glycosylation to rescue and alter gating of the NaV1.5-Na+ channel
Wang, P., Zhu, X., Wei, M., Liu, Y., Yoshimura, K., Zheng, M., Liu, G., Kume, S., Kurokawa, T., & Ono, K. (2021) · Heart and Vessels · doi:10.1007/s00380-020-01736-4 · Cited by 3
Metadata
- Authors
- ACADEMIE Study Investigators, Imaizumi, S., Shiga, Y., Ogawa, M., Sako, H., Nagata, Y., Matsunaga, A., Shirotani, T., Hoshino, F., Yahiro, E., Uehara, Y., Morito, N., Tanigawa, H., Shimono, D., Fukushima, M., Sugihara, H., Norimatsu, K., Kusumoto, T., Saku, K., & Miura, S.-I.
- Affiliations
- Fukuoka University (JP)
- Corresponding author
- Miura, Shin-ichiro
- Venue
- Heart and Vessels
- Published
- 2018-11-08
- Volume
- 34
- Issue
- 4
- Pages
- 698-710
- ISSN
- 0910-8327 (ISSN-L)
- 1615-2573
- OpenAlex
- W2900052565
- Cited by
- 3
- References
- 41
- Citations by year
- 2022: 1 · 2021: 2
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-04-10)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Heart and Vessels (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Dainippon Sumitomo Pharma
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- type 2 diabetes, essential hypertension, uncontrolled hypertension, amlodipine, calcium channel blockers, angiotensin receptor blockers, adjunctive therapy, blood pressure control, home blood pressure monitoring, remote patient monitoring, combination antihypertensive therapy
- MeSH terms
- Essential Hypertension, Aged, Blood Pressure, Calcium Channel Blockers, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Treatment Outcome, Amlodipine, Blood Pressure Monitoring, Ambulatory, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.